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Abstract Childhood cancer is rare, with an incidence of 100
new cases per million children and with renal tumours
contributing 7% of cases. The introduction of multimodality
treatment, surgery, radiotherapy and chemotherapy, has led to
an exponential increase in the 5-year survival rate to >80%.
However, thissuccessfultreatment has led tothe development
of late adverse effects. These treatment-related effects can
cause premature deaths and increased morbidity compared
with patients’ peers. Radiation causes damage to tissue and
organs within the radiation field, affecting growth and
function, and is largely responsible for the leading cause of
death, namely, second malignant neoplasms. Another impor-
tant late effect is cardiac dysfunction due to anthracycline use
with or without cardiac radiation. In addition, a few patients
have genetic abnormalities predisposing to Wilms tumour
development, which result in renal dysfunction in the long
term and may be exacerbated by cancer treatment regimens.
Awareness of late consequences of cancer treatment is
important, as early recognition can improve outcome. When
presented with a patient with a history of renal tumours, it is
vital to enquire about previous treatment to understand
whether it is relevant to the presenting problem.
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Introduction
Childhood cancer is rare, with an incidence of 100 new
cases per million children and with renal tumours contrib-
uting 7% of cases: approximately 100 new cases per year.
There are several different types of renal tumours diagnosed
during childhood, both benign (mesoblastic nephroma) and
malignant [Wilms tumour (WT), clear-cell sarcoma of the
kidney, renal rhabdoid, renal-cell carcinoma]. By far the
commonest is WT (nephroblastoma) at 85%. Therefore, the
majority of long-term follow-up studies feature WT
survivors. Treating renal tumours has been highly success-
ful since the introduction of multimodality treatment, with a
5-year survival rate that has increased dramatically over the
last three decades from 25% in the prechemotherapy era of
the late 1960s and early 1970s, to 90% in the 1990s [1].
Treatment, by design, is cytotoxic and at present is
unfocused, so that damage occurs to both cancer cells and
normal tissue. The extent of the damage depends on many
factors, including patient demographics, genetic factors and
treatment modalities and doses required to cure the cancer.
The majority of renal tumours occur in young children with
WT presenting at a mean age of 3 years. These young
patients are highly vulnerable to tissue damage, as the
normal growth and development may be affected.
The improving survival rate extending over three
decades has enabled good long-term outcome studies to
be conducted, providing valuable information to inform
follow-up and to improve health status for future patients.
This information on treatment-related late effects comes
from a variety of studies, including large epidemiological
(population/multicentre) and single/multicentre studies. The
use of multimodality options has been incorporated into the
regimens since the 1980s and consists of surgery, chemother-
apyandradiotherapy,withintensitydependingonhistological
diagnosis, disease extent and treatment era [2]. Commonly
used drugs are vincristine, actinomycin D, anthracyclines
(doxorubicin) and alkylating agents (cyclophosphamide,
ifosphamide). More recent protocols incorporate carboplatin
andetoposideinhigh-riskpatients.Radiotherapyisprescribed
if the disease is outside the resected kidney or there is
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total radiation dose and fractionation (daily dose) has changed
over the years in an attempt to reduce late effects. Lower total
radiation dose given in smaller fractions is beneficial. Surgery
generally comprises total nephrectomy, but there is interna-
tional debate about the value of partial nephrectomy. In
bilateral disease or in patients with a predisposition syndrome
and at increased risk of developing metachronous tumours, an
attempt is made to preserve renal tissue by performing partial
nephrectomy.
In this review, we address the major late consequences that
occur in survivors of childhood renal tumours, including late
mortality, cardiovascular, renal, reproductive function and
development of second malignant neoplasms (SMN). Late
effects of treatment are defined as clinical or subclinical
consequences that persist or appear >5 years after diagnosis.
Late mortality (mortality occurring >5 years
from diagnosis)
Mortality studies are robust and largely predate comprehen-
sivemorbiditystudies.Theyleadthewaytounderstandingthe
late effects of cancer treatment, and for this reason, they are
discussed first. Three large epidemiological studies have been
published in the last few years. The multicentre American
Childhood Cancer Survivors Study (CCSS), the National
Wilms Tumor Study Group (based in North America) with
patient overlap with CCSS and the population-based British
Childhood Cancer Survivors Study (BCCSS), all of which
assessed causes of death in patients who had survived 5 years
from their cancer diagnosis [3–5]. These studies showed that
although long-term outcome is excellent, renal cancer
survivors are at risk of premature death. Mortality studies
in the UK and USA identified an overall standardised
mortality ratio of 5.8–4.9 in patients treated from 1940 to
1991 and 1969 to 1995, respectively [3, 5]. Early deaths
(<5 years from diagnosis) are mainly due to disease relapse
compared with late mortality, for which studies identify a
crossover of causes, with fewer deaths due to disease
recurrence and more due to treatment-related causes. Over
time from diagnosis, the risk of premature death fell from a
13-fold at 5–10 years from diagnosis to 5-fold at 30 years
compared with age- and sex-matched peers in the general
population [4]. Encouragingly, there is a trend that more
contemporary patients may be at less risk of premature death
[3]. Analysis of the causes of late deaths across all reports
identified SMN as the leading cause, followed by cardiac
and pulmonary disease [3–5].
Overall late morbidity
Following on from the mortality studies, two studies
reported on overall morbidity: a patient questionnaire
study from the American CCSS [6] assessed 1,256 WT
survivors diagnosed between1970 and 1986, and Greenan
et al. published a smaller study using clinically obtained
data in 189 survivors from a single centre who were
diagnosed between 1966 and 2004 [7]. In the latter study,
29% of survivors had no adverse effects, and 12%
demonstrated a high or severe burden of adverse effects.
The authors emphasised the increased risk of cardiovas-
cular problems after anthracyclines and thoracic and/or
abdominal radiation, with relative risks (RR) of 3.55
[95% confidence interval (CI) 1.52–8.20] and 2.36 (95%
CI 1.69–3.29), respectively. The large multicentre study
reported a cumulative incidence of severe chronic health
conditions of 24% at 25 years. Interestingly, compared
with sibling controls, there was no difference in mental
health status, socioeconomic outcome and health-care
use [6].
Cardiotoxicity
Cardiotoxicity is a leading cause of morbidity due to
the use of anthracyclines (doxorubicin is commonly
used) and radiation when the radiation field involves the
heart. Anthracyclines wer ea d d e dt ot h et r e a t m e n t
regimen in the late 1970s, with the immediate benefit
of increasing survival in high-stage disease. Since their
early use, there has been an appreciation of their
preferential myocyte toxicity causing cardiomyopathy.
Clinical heart failure is the most common presentation,
which may occur acutely or many years from the
completion of treatment [8, 9]. In a single-centre British
study, cardiac function was evaluated 1.0–18.8 (mean
7.1) years after completion of treatment in 97 children
whose therapy for WT included an anthracycline (mean
cumulative dose 303 mg/m
2)[ 10]. Subclinical cardiac
abnormalities, identified by detailed echocardiograms,
were found in 25% of patients. In multivariate analysis
that included cardiac radiation (from lung and left-flank
radiation), only increasing cumulative dose and dose
intensity were significant risk factors for impaired cardiac
function. With longer follow-up, an American study
reported that the cumulative risk of clinical congestive
heart failure 20 years after diagnosis was 4.4% in relapse-
free WT patients whose treatment included anthracyclines
with or without cardiac irradiation, and this increased
markedly to17.4% in survivors of relapsed WT [11, 12]. A
number of studies have highlighted the progressive nature
of the damage, with an increasing life-long risk of
developing clinical cardiac dysfunction, which may
necessitate a cardiac transplant [13–15]. Follow-up
involves regular echocardiography, the frequency of
which depends upon the possible risk of progressive
disease [16].
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As expected, there is a degree of renal impairment in
survivors of renal cancer, although recent studies are
reassuring [17]. Renal function can be affected by all
treatment modalities: surgery reducing the renal mass,
radiation to the remaining kidney(s) or nephrotoxic chemo-
therapeutic agents (Ifosphamide, carboplatin), in addition to
genetic conditions. Encouragingly, renal disease is not a
major issue for uncomplicated unilateral renal tumours.
Patients at maximum risk of end-stage renal disease are
those with bilateral disease, occurring either synchronously
and metachronously or in association with a WT-1 mutation
[WT–aniridia syndrome (WAGR), Denys–Drash and the
rarer Frasier syndrome] [18]. A study using the National
Wilms Tumour Study Group database between 1969 and
1994 identified a cumulative incidence of end-stage renal
failure at 20 years in unilateral disease to be 0.6% when
there was no evidence of WT-1 mutation or genitourinary
anomalies. However, renal failure occurred in 74% of those
with accompanying Denys–Drash syndrome, 36% in
WAGR patients and 7% in male patients with cryptorchi-
dism or hypospadias. In those with bilateral disease, end-
stage renal disease occurred in 12%, with a higher
incidence in WAGR patients of 90%, and 20% in males
with associated genitourinary anomalies [18]. Interestingly,
patients with intralobar nephrogenic rests identified in the
healthy part of the kidney but with no known predisposition
had a slightly increased risk of renal disease compared with
those with healthy kidney surrounding the WT [19].
Survivors of childhood cancer who have undergone
nephrectomy or bilateral partial nephrectomy may be at risk
of late hyperfiltration injury and/or hypertension. Compensa-
tory hypertrophy of the remaining kidney is a well-
documented finding after nephrectomy [20, 21]. Although
this adaptation may initially increase glomerular filtration
capacity, there may be a later development of glomerulo-
sclerosis [22, 23], and interstitial injury [23] may ultimately
lead to renal function deterioration. The prevalence of
microalbuminuria, which is indicative of glomerular hyper-
filtration, following nephrectomy for WT is less clear and has
been reported to range from 5% to 84% [24, 25]. Diastolic
hypertension has been reported, although the incidence is
variable: from 0–7% [18, 20, 24]. In a large analysis of 1,171
children treated for WT whose blood pressure was measured
5 years after diagnosis, 83 (7%) had a diastolic blood pressure
>95th percentile for age [24]. The relative contribution of
nephrectomy to this complication was unclear because a
substantial proportion of patients with diastolic hypertension
had also received abdominal radiotherapy.
Ifosfamide has been used in some protocols for first-line
treatment in high-stage disease and in relapse protocols.
This alkylating agent is nephrotoxic, causing both tubular
(Fanconi’s syndrome) and glomerular damage [26, 27]. The
risk of developing nephrotoxicity is related to the total
cumulative dose of Ifosfamide (>60–100 g/m
2)[ 25–27] and
to patient-related factors such as the presence of a single
kidney [28], renal irradiation [29] and young age [30–32].
Clearly, patients with WTare at particular risk. The prognosis
of the nephropathy is variable, with some patients no longer
requiring electrolyte supplementation and others progressing
to renal failure [33]. In tumour relapse, patients can be
salvaged with a combination of agents—ifosfamide,
carboplatin and etoposide, which is nephrotoxic—and
careful monitoring is required [34]. The recommenda-
tions for survivor follow-up are regular urinanalysis and
blood pressure monitoring, with more intensive follow-up
in the at-risk patients [17].
Fertility and pregnancy outcomes
Of great concern to survivors is the issue of fertility and
whether their offspring will be affected by their previous
treatment. The first-line chemotherapy used, in general,
does not affect either ovarian reserve or male fertility.
Cyclophosphamide used in high-risk patients may affect
sperm count, but it is unlikely to cause ovarian failure [35].
Ifosfamide can affect fertility, but the doses used in the
relapse protocols are lower than shown to cause gonadal
damage [36]. Abdominal radiation has a more detrimental
effect on female reproduction. Radiation to the abdomen
usually involves the pelvis, and therefore, the ovaries and
uterus may be in the field and at risk of damage. Whole-
abdomen radiation usually results in primary ovarian failure
or premature menopause. Several studies demonstrated that
the offspring of women who received flank radiation for
WT were more likely to have a birthweight <2,500 g,
prematurity and foetal malposition than were those born to
women whose protocol treatment did not include flank
irradiation [37–39]. An added complication is the unusual
finding that genitourinary anomalies are known to occur in
WT patients, including Müllerian duct anomalies, with
septate/unicornuate uteri occurring [39, 40]. Nicholson et
al. reported uterine abnormalities in 8% (2 of 24) of female
WT patients, one of whom had WAGR syndrome [40].
Second malignant neoplasms
The occurrence of second tumours within the cancer
population, either benign or malignant, is a well-
recognised late sequel of therapy, and WT survivors are
no exception. The less serious occurrence of osteochon-
dromas, or benign bone tumours, may be associated with
radiation of the epiphysis of growing bone. These tumours
can cause pain, affect function and be unsightly, requiring
surgical intervention [41–43]. Interestingly, these tumours
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whom had a family history of multiple exostoses [44, 45].
Patients exposed to radiotherapy, certain chemotherapy agents
orwith a known familialcancerpredisposition syndrome have
all been demonstrated to have an increased risk of second
cancers. Studies across a number of countries have given a
range of cumulative incidence of 0.65–0.8% at 10 years,
increasing to 4.8–7.0% at 30 years, with no obvious plateau.
Radiation therapy has been consistently shown to be an
important contributory factor in the excess risk of subsequent
cancers. Breslow et al. reported that 73% of second solid
tumoursoccurredwithintheradiotherapyfield,andtheyfound
clear evidence of an increase in the risk of second cancer with
increasingdosesofradiation[46]. This is supported by Taylor
et al., who reported that 35 of 39 solid tumours were within
the radiation field and the majority had an estimated radiation
dose of >25 Gy [47]. An international analysis of SMN in
WT survivors showed a consistent rate across countries [48].
Tumour types vary; they include bone and soft-tissue
sarcomas, breast cancer, lymphoma, tumours of the digestive
tract and melanoma [46, 47]. Acute leukaemias also occur,
particularly in patients treated in the modern era. It has been
postulated that this may be due to more intensive chemo-
therapy regimens [48].
Other late effects
Radiotherapy causes disruption of tissue growth and
therefore these young patients, in addition to the main late
effects, do exhibit poor development of both muscle and
bone within the radiation field. For example, patients who
received flank radiation have reduced final height because
of poor growth of the irradiated spine, with the degree of
shortening depending on the dose and age at treatment. In
addition, there is soft-tissue hypoplasia with truncal
asymmetry when flank radiation has been given [49, 50].
In the recent BCCSS study, the Physical Component Score
(PCS) analysis showed a normal result in the younger age
range (16–19 years) but worsened with age so that survivors
>35 years showed a significant difference in mean PCS score,
with values of −3.0 compared with population norms.
Females performed consistently worse than males. Twenty-
five percent stated they could not walk a mile, with 9% being
unable to walk 100 yards [51]. From a socioeconomic aspect,
WTsurvivors compare well with the general population with
comparable educational attainments [51], employment [52]
and mental health outcomes [51, 53, 54].
Conclusions
In this review, we addressed the potential late consequences of
successfultreatmentforchildhoodrenaltumours.Itisimportant
to view these late consequences within the context of the wider
clinical picture. WT treatment has been a success story, and
>80%ofchildren diagnosed withWTcanlookforwardtolong-
term survivorship. The late complications are a consequence of
the type and intensity of treatment required, which in turn
reflects the nature and extent of the original tumour. The late
effects reported here are a reflection of treatments given over
many decades, and the next generation of treatment protocols
hopefully will cause less problems as international groups
design new strategies to try to reduce late sequelae. From a
nephrology perspective, the majority of survivors have few
renalproblems. In thefuture,geneticresearchmay well identify
those at particular risk who will then require specialised
nephrology follow-up. For all survivors, there is a need for
long-term follow-up programmes to be developed, with
individualised follow-up plans designed to optimise the
patient’s knowledge of long-term risks, in addition to providing
specific clinical surveillance to achieve early diagnosis of
sequelae and determine effective management [17, 55].
Questions (Answers appear following the reference list)
1. Which treatment modality is responsible for the
majority of late effects?
(a) Surgery
(b) Radiotherapy
(c) Alkylating agents
(d) Anthracyclines
(e) Carboplatin
2. Which subset of patients are at significant risk of renal
failure?
(a) Unilateral disease with genitourinary abnormalities
(b) Beckwith–Wiedemann syndrome
(c) Bilateral disease
(d) Treatment with anthracyclines
(e) WAGR patients
3. Which of the following is true about anthracyclines?
(a) Cause stunted growth
(b) Late effect is associated with total dose administered
(c) Cardiotoxicityseeniscommonlyduetodysrhythmias
(d) After the initial hit, there is no progression of
cardiac disease
4. Which of the following is true about second tumours?
(a) Always malignant
(b) Generally occur outside the radiation field
(c) Occur many decades from the original treatment
(d) Caused primarily by chemotherapy
5. Which of the following is true about effects on fertility?
(a) Males are more at risk of infertility than females
after treatment for Wilms tumour
914 Pediatr Nephrol (2012) 27:911–916(b) Etoposide is the drug commonly associated with
infertility
(c) The foetus is at risk of hydramnios
(d) Premature births occur more frequently in patients
who have not received radiation
(e) Offspring are generally not at risk of developing
WT
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